|Articles|July 1, 2009

IRBs Role Today

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© photon_photo - © photon_photo - stock.adobe.com

Before Burden Becomes Risk: Capturing Friction in Real Time

ByBrian S. McGowan, PhD, FACEHP,Kelly Ritch,Jason Riis, PhD

July 13th 2026

What Program-Level Recruitment Requires from Sponsors Operationally

ByGaynor Anders,Andy Studna, Senior Editor

July 13th 2026

ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development

ByAndy Studna, Senior Editor

July 13th 2026

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ByAndy Studna, Senior Editor

July 10th 2026

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

ByGaynor Anders,Andy Studna, Senior Editor

July 10th 2026

IRBs Role Today

Related Content

Before Burden Becomes Risk: Capturing Friction in Real Time

What Program-Level Recruitment Requires from Sponsors Operationally

ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Trending on Applied Clinical Trials Online

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation